Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin)
a lowering of the frequency of systemic side effects, compared to nontargeted standard chemotherapy regimens. However, unexpected toxicity has been observed after ADC therapies, through several potential mechanisms: expression of the antigenic target by normal tissues; innocent bystander effects related to organ involvement by tumor; uptake of ADCs by liver sinusoidal endothelial cells (LSECs); and disposition of the toxic moiety resulting in damage to excretion pathways. (1) (2) (3) (4) An example of unexpected toxicity was observed after treatment of acute myeloid leukemia with the CD33 antigen-targeted immunoconjugate, N-acetyl dimethyl hydrazide calicheamicin (gemtuzumab ozogamicin [GO] ; Mylotarg), which caused liver toxicity. (5, 6) Presentation of this toxicity, however, did not fall into a standard classification of drugInduced Liver Injury (DILI), but rather presented with signs and symptoms of acute portal hypertension, caused by damage to LSECs, embolization of LSECs and hepatocytes, activation of stellate cells, and deposition of collagens into liver sinusoids, resulting in obstruction to sinusoidal blood flow. (7, 8) The resulting sinusoidal obstruction syndrome (SOS; formerly known as veno-occlusive disease [VOD] of the liver) was similar in its presentation and course to acute sinusoidal injury caused by regimens of high-dose chemotherapy and irradiation used to prepare patients for hematopoietic cell transplantation (HCT). (9, 10) A prominent histological feature of GO-caused SOS is deposition of collagens within sinusoids, a result of activation of hepatic stellate cells (HSCs). (7, 11) Stellate cells are activated when sinusoidal endothelial cells (SECs) are damaged, resulting in loss of a signal that keeps stellate cells in a quiescent state. (12) Inotuzumab ozogamicin (InO), an immunoconjugate with the same calicheamicin moiety as GO, but targeted at leukemia and lymphoma cells expressing CD22, has the potential to cause the same sort of sinusoidal liver damage as GO, but with one significant difference: There are no cells in the normal liver that express CD22, with the exception of lymphocyte populations resident in the liver (mostly confined to portal areas). If SOS that occurs after GO is related to targeting of CD33-expressing cells normally resident in hepatic sinusoids, frequency of SOS after therapy with InO should be significantly less. However, because hepatic sinusoids are often a reservoir of leukemic cells in patients with refractory CD22 + acute lymphocytic leukemia (ALL), and portal areas are frequently infiltrated with CD22 + lymphoma cells in patients with non-Hodgkin's lymphoma (NHL), the opportunity exists for a bystander effect on the liver following treatment with InO. (13) (14) (15) Alternatively, if endocytosis of ADCs by the FcγRIIb2 receptor on LSECs is the proximate cause of LSEC damage, frequency of SOS following InO therapy could be similar to that following GO therapy, even though there are no CD22 + cells in normal hepatic sinusoids, except for CD22 + malignant cells. These are not mutually exclusive mechanistic hypotheses.
In the studies reported here, a panel of hepatologists familiar with DILI and sinusoidal liver injury reviewed all subjects with liver abnormalities following InO therapy in two multicenter protocols. randomized patients with relapsed or refractory ALL to single-agent InO versus one of three investigator-choice standard chemotherapy regimens, as described. (16) The other study randomized patients with NHL to InO plus rituximab versus an investigator-choice standard chemotherapy regimen. (17) Liver abnormalities were categorized by our panel (blinded to treatment assignment) into one or more diagnostic categories (Table 1) on the basis of clinical presentation, laboratory and imaging tests, proximity to study drug, clinical course, and liver histology, when available. We categorized the causes of liver abnormalities in the following subcohorts of patients: InO-treated patients with ALL; InO-treated patients with NHL; patients with ALL treated with standard chemotherapy; and patients with NHL treated with standard chemotherapy.
Patients and Methods

patIeNt SelectIoN
All subjects with either ALL or NHL who were randomized and treated according to randomization assignment (InO vs. standard therapy control) were eligible for review of adverse events involving the liver. There were two separate randomized, phase 3, multicenter studies sponsored by Pfizer Incorporated (New York, NY). Protocol B1931008 (formerly Wyeth 3129K5-3303-WW; NCT01232556) evaluated the efficacy and safety of InO, a CD22-targeted antibody linked to the toxic agent, calicheamicin, in combination with rituximab in subjects with relapsed/ refractory aggressive NHL, compared to an active control arm consisting of the investigator's choice between two rituximab (R)-containing chemotherapy regimens, R-bendamustine or R-gemcitabine. (17) Study B1931022 (NCT01564784, the INO-VATE study) evaluated the efficacy of InO in an open-label trial in subjects with relapsed or refractory CD22 + ALL, compared to an active control group of subjects who received one of three regimens chosen by study site investigators (FLAG, fludarabine, cytarabine, and granulocyte colony-stimulating factor [G-CSF] for up to four cycles; or cytarabine and mitoxantrone for up to 4 cycles; or HIDAC, high-dose cytarabine for up to 12 doses per cycle for up to 2 cycles). (16) In these trials, InO was given intravenously for up to six cycles at a dose of 1.8 mg/m 2 per cycle (potential maximum InO exposure, 10.8 mg/m 2 ), as described. (16) Once complete remission was achieved, InO dose was decreased to 1.5 mg/m 2 /cycle for all other cycles. In Study B1931022, InO was given in split/weekly doses (3 doses per cycle) whereas in Study B1931008, InO was given as a single dose per cycle. The majority of patients in the InO arm received one to four cycles of 
MoNItoRINg oF aDVeRSe eVeNtS INVolVINg tHe lIVeR
Hepatobiliary adverse events were identified when either liver-related adverse events were reported by a clinical site investigator or identified by the Pfizer Study Team during periodic data review. There were two "study periods" during which Pfizer gathered data about hepatobiliary complications. The first period included events during study treatment (with either InO or the control standard chemotherapy) and included events through 28 days after the last dose of study drug or the end-of-treatment visit, whichever occurred later. The second period included any study treatment-related events after this for up to 2 years after randomization. Potential hepatobiliary events included, but were not limited to, the following: abnormal serum liver tests (alanine [ALT] and aspartate aminotransferase [AST], alkaline phosphatase [ALP], gamma glutamyl transpeptidase [GGT] , and total serum bilirubin); clinical diagnoses of hepatic VOD or SOS, nodular regenerative hyperplasia, liver failure, multiorgan failure, cirrhosis or hepatic fibrosis, right upper-quadrant pain, abdominal pain thought to be hepatobiliary in origin, ascites, hepatomegaly, and any event that fell under the System Organ Class MedDRA query for hepatobiliary disorders. For each subject identified as having a liver-related adverse event, the Pfizer Study Team prepared a dossier of data that was de-identified as to randomization assignment, consisting of (1) a summation of Serious Adverse Event forms; (2) subject narrative (demography, medical history, previous therapy for the underlying malignancy, including conditioning therapy for HCTs, hepatic history, surgical history, nonstudy medications-including herbal supplements and herbal teas-vital signs, changes in weight, results of physical examination, laboratory values, sites of malignant disease, other adverse events, and other nonstudy treatments); (3) start dates of each study drug cycle (study drug was not identified); (4) hospital discharge summary and other relevant medical/hospital records such as consultation reports; and (5) Freston as the tie-breaker for both studies in the event of disagreement as to classification). HEAB deliberations for each subject resulted in one or more liver disease classifications as shown in Table 1 , that is, the classifications were not mutually exclusive. The classification "other hepatic disease" was accompanied by a description as to the nature of the liver disorder. The classification "not a hepatic event" was applied to situations where the signs, symptoms, and laboratory result were not of liver origin, for example, abdominal pain of gastrointestinal and not liver origin. The classification "not enough information to classify" was applied when there was a paucity of clinical data to explain a liver-related abnormality. When the HEAB classified a subject as having SOS, it was accompanied by an opinion as to certainty of diagnosis (definite, probable, or possible) and severity (mild, moderate, or severe). When the HEAB identified more than one hepatobiliary adverse event during the study period, the most serious diagnosis was identified by Dr. McDonald according to a rule-based system: SOS was listed as the most serious diagnosis whenever it was identified. Otherwise, the diagnosis with the highest total serum bilirubin in closest proximity to assigned therapy was identified and carried forward as the classification in statistical analyses.
StatIStIcal aNalySIS
Frequency of liver-related adverse events in both studies was analyzed separately for events that occurred after randomization and the assigned treatment, and events that occurred after a subsequent conditioning regimen (also known as the preparative regimen) and infusion of donor cells (hematopoietic cell transplantation). Frequency of occurrence of liver disease classifications (as determined by the HEAB) in the InO arm was compared to that in the control arm by Fisher's exact test. For the subset of patients with ALL enrolled in Study B1931022 who subsequently underwent HCT, uni-and multivariate analyses were conducted to identify potential risk factors for posttransplant development of SOS. In the univariate analysis, for each potential risk factor, frequency of the categorical variable or distribution of the continuous variable was compared between patients who developed SOS after HCT and those who did not develop SOS after HCT. P values from Fisher's exact test and Wilcoxon's ranksum test were reported for categorical variables and continuous variables, respectively. Factors with a P value <0.10 in the univariate analysis were included in the multivariate logistic regression modeling using stepwise selection. A significance level of 0.3 was required to allow a variable into the model and a significance level of 0.1 was required for a variable to stay in the model.
Results
LIVeR DISoRDeRS tHat occURReD DURINg aND aFteR tReatMeNt oN pRotocol, BeFoRe Hct liver Disorders in patients With all
Overall frequency of liver disorders in patients with ALL (Study B1931022) as reviewed by the HEAB was numerically, but not significantly, greater in patients randomized to receive InO than in those receiving a standard chemotherapy regimen (22.6% vs. 16.8%; P = 0.2515; Table 2 ). In the InO arm, there were 2 cases of severe SOS (1 scored as definite, 1 as probable) and 1 case of mild SOS, scored as probable; no cases of SOS were found in the standard chemotherapy arm (1.8% vs. 0%; P = 0.2511). There were significantly more cases of DILI (that did not meet criteria for SOS) in the InO arm, compared to the standard chemotherapy arm (7.9% vs. 1.4%; P = 0.0079). Frequency of other liver disorders was not significantly different in the two arms, including intrahepatic cholestasis (6.1% in the InO arm vs. 11.2% in the standard chemotherapy arm; P = 0.1495). Most of the cases of cholestasis were in the setting of febrile neutropenia and infection.
liver Disorders in patients With NHl
Overall frequency of liver disorders was significantly greater in patients randomized to receive InO-R than in those receiving standard chemotherapy (26.8% vs. 7.8%; P = 0.0001; Table 2 ). In the InO-R arm, there were 2 cases of SOS (1 scored as possible and mild, 1 as possible and moderate); no cases of SOS were found in the standard chemotherapy arm (1.2% vs. 0%; P = 0.2447). In the InO-R arm, there were significantly more cases of DILI, compared to the standard chemotherapy arm (7.9% vs. 0.6%; P = 0.0007) and more cases classified as "other hepatic disease" (9.1% vs. 2.4%; P = 0.0091). The disorders covered by the "other hepatic disease" classification encompassed Gilbert's syndrome and minor elevations of total serum bilirubin or liver enzymes remote from treatment periods that did not meet criteria for DILI (see Table 2 , footnotes "ǁ" and " ¶"). The reason for the greater frequency of "other hepatic disease" in recipients of InO-R is not readily apparent, but it is possible that this category includes some instances of DILI with a delayed appearance. Frequency of cirrhosis, noninfectious hepatitis, IHC, and biliary obstruction was not significantly different in the two arms.
comparison of the Frequency of Specific liver Disorders in Ino-treated Subjects, by Underlying Diagnosis (all vs. NHl), Before Subsequent Hct
During study therapy, overall frequency of liver disorders was similar among InO recipients with • Increased unconjugated serum bilirubin caused by Gilbert's syndrome (n = 1)
• Budd-Chiari syndrome, later development of refractory GVHD with liver involvement (n = 1)
• Following sepsis syndrome, development of hypoxic hepatitis and cholestasis of infection (n = 1)
• Increased unconjugated serum bilirubin from hemolysis, minimal liver enzyme elevation, cause unknown (n = 1) § Control arm: Of the 4 ALL patients classified as "other hepatic disease," these were the clinical situations:
• Liver toxicity caused by ponatinib, GVHD, and leukemia in the liver (n = 1)
• Following sepsis syndrome, development of hypoxic hepatitis and cholestasis of infection (n = 2)
• Evidence was present for GVHD, hypoxic hepatitis, and cholestasis of infection (n = 1) ‖ InO-R arm: Of the 15 lymphoma patients classified as "other hepatic disease," these were the clinical situations:
• Increased unconjugated serum bilirubin, Gilbert's syndrome or hemolysis (n = 2) • Increased total serum bilirubin, months after InO-R exposure, cause unknown (n = 2)
• Increased serum liver enzymes, no clear relation to InO-R exposure, cause unknown (n = 11) ¶ Control arm: Of the 4 lymphoma patients classified as "other hepatic disease," these were the clinical situations:
• Increased unconjugated serum bilirubin, Gilbert's syndrome or hemolysis (n = 1)
• Increased serum liver enzymes, no clear associations, cause unknown (n = 2)
• Ascites, cause unclear, tumor or pre-existing liver disease (n = 1) # InO arm: For the ALL patient classified as "not enough information," this was the clinical situation:
• Mild increase in total serum bilirubin (mostly unconjugated) in InO cycles 1, 4-6; other liver tests normal; no further evaluation at study site **InO-R arm: Of the 2 lymphoma patients classified as "not enough information," these were the clinical situations:
• Delayed increase in ALP, GGT, and bilirubin after InO-R exposure, not investigated at study site (n = 1) • Increased total serum bilirubin after febrile neutropenia, not investigated at study site (n = 1) † † Control arm: Of the 2 lymphoma patients classified as "not enough information," these were the clinical situations:
• Ascites detected before and after therapy, cause unknown (lymphoma or pre-existing liver disease; n = 1)
• One day with mildly increased serum AST/ALT, not repeated (n = After randomization and treatment on Study B1931022, 79 subjects who had received InO and 34 who had received only standard chemotherapy, including additional salvage therapy in some patients, proceeded to conditioning therapy (also called the preparative regimen, consisting of chemotherapy drugs with or without total body irradiation) for allogeneic HCT. Overall frequency of liver disorders was greater in patients previously exposed to InO before subsequent HCT than in those who had previously received standard chemotherapy (34% vs. 12%; P = 0.0203; Table 3 ). Overall frequency of SOS in those previously exposed to InO was 21 of 79 (27%) versus 3 of 34 (9%) in those previously exposed to standard chemotherapy (P = 0.0442). Moderateto-severe SOS developed after HCT in 19 of 79 (24%) InO-exposed subjects, compared to 3 of 34 (9%) who had previously received only standard chemotherapy (P = 0.0726).
Risk Factors for Development of SoS in patients With all treated on Study B1931022
We examined potential risk factors for development of SOS after HCT according to demographic factors, past medical history, time of randomization-to-HCT factors, and factors related to the HCT procedure, including conditioning therapy, donor type, and graft-verus-host disease (GVHD) prophylaxis. By univariate analysis, factors associated with development of SOS after HCT at the P < 0.05 level of significance included older age (P = 0.0435); HCT before study therapy (P = 0.0230); history of liver disease before study entry (P = 0.0073); exposure to InO (P = 0.0442); ALP level during the study period and just before conditioning therapy (P = 0.0004 and P = 0.0001, respectively); and low leukocyte and platelet counts just before conditioning therapy (P = 0.0439 and P = 0.0004, respectively; Table 4 ). A multivariate model was developed in which all factors related to development of SOS after HCT with a P value <0.10 based on univariate analysis were considered for entry. After stepwise selection, factors that remained in the final model included HCT before study therapy, history of liver disease, ALP level before conditioning therapy, thrombocytopenia before conditioning therapy, and GVHD prophylaxis with a calcineurin inhibitor and methotrexate. Among these factors, history of liver disease (odds ratio [OR], 3.498, 95% confidence interval [CI], 1.065-11.492) and thrombocytopenia before start of conditioning therapy (OR, 4.223; 95% CI, 1.279-13.939) were associated with a P value <0.05 ( Table 5 ). The multivariate analysis confirmed observations in the univariate analysis, and suggested that these two factors may be associated with a higher risk of SOS after HCT. Risk factors that were significant in the univariate analysis that did not enter the multivariate model were previous exposure to InO, older age, ALP levels during the study period, and low leukocyte counts. However, given that the analysis was done in a relatively small sample size without multiplicity adjustment, we consider these results to be suggestive and hypothesis generating.
DIScoRDaNt lIVeR DIagNoSeS IN patIeNtS WItH ALL, aS MaDe By StUDy SIte INVeStIgatoRS VeRSUS HEAB HepatologIStS
Most of the Study B1931022 cases reviewed by the HEAB because of hepatobiliary problems had been reported by study-site investigators with descriptive terms such as hyperbilirubinemia, elevated liver enzymes, liver test abnormalities, liver dysfunction, and ascites, without providing an underlying diagnosis. Two subjects who received InO and whose liver problem was termed "ascites" by investigators were classified by HEAB as having intra-abdominal tumor and pancreatic ascites, respectively. Of 6 subjects whose liver problems after randomization were given specific diagnoses by study-site investigators, two were discordant with HEAB diagnoses, both termed VOD by investigators, but classified as IHC by the HEAB (Table 6 ). Of 23 subjects in whom study investigators had reported specific liver diagnoses following HCT, 3 were discordant with HEAB diagnoses. One discordant case, previously exposed to InO, carried an investigator diagnosis of VOD that the HEAB classified as IHC plus nonalcoholic steatohepatitis (NASH). Two discordant cases, both previously exposed to InO, were discordant only in a technical sense (investigator diagnoses were "hepatotoxicity" and "multi-system dysfunction"-both were HEAB-classified as SOS).
Discussion
Liver toxicity, specifically injury to hepatic sinusoids, is a major concern for development of ADCs. (4) There are four potential mechanisms for hepatic injury from ADCs: (1) targeting of normal sinusoidal cells that express the same antigen as expressed on malignant cells; (2) uptake of ADCs by endocytosis by LSECs and Kupffer cells (KCs); (3) presence of malignant cells in hepatic sinusoids that express the antigen of interest, resulting in release of toxin into sinusoids after apoptosis of malignant cells; and (4) damage to disposition pathways caused by exposure to a metabolite of the toxic moiety. The ADC, InO, is a CD22-targeted humanized immunoglobulin type G, subtype 4 antibody covalently linked to N-Ac-γ-calicheamicin dimethylhydrazide. There is intracellular release of the cytotoxic component (N-Ac-γ -calicheamicin dimethylhydrazide), which then is metabolized by nonenzymatic reduction, followed by biliary elimination. These are not mutually exclusive mechanisms for liver injury following ADCs. The major findings by our panel of hepatologists from the two randomized trials of single-agent InO or InO-R versus standard chemotherapy drug regimens for the malignant disorders ALL and NHL are the following:
1. The combined frequency of SOS (all degrees of severity and certainty of diagnosis) among patients who received InO was 5 of 328 (1.5%), compared to no cases among 310 who received chemotherapy regimens (Table 2) . Among 638 randomized patients, severe SOS was observed only in 2 ALL patients following InO treatment (0.3%). 2. Overall frequency of SOS was similar between those treated with InO for ALL versus those treated with InO-R for NHL (Table 2 ). 3. A more frequent liver complication among patients who received InO was DILI ( Table 2) . The frequency of DILI in ALL study participants was significantly more frequent among recipients of InO (7.9%) than among those randomized to standard chemotherapy alone (1.4%; P = 0.0079). In the NHL study, similar increased frequencies of DILI were observed (7.9% in the InO group vs. 0.6% in the standard chemotherapy group; P = 0.0007). For the most part, manifestations of DILI were transient and asymptomatic elevations of serum ALT, ALP, or total serum bilirubin, without evidence of portal hypertension, weight gain, or fluid accumulation. We could not determine with any certainty whether DILI was related to InO exposure or toxicity from concomitant medications or from hepatic effects of concomitant infection, much less to define the exact drug that was responsible for DILI. For example, most patients in both arms of both protocols received antibiotics, antifungal drugs, and antiviral drugs as prophylaxis, pre-emptive coverage (especially for viral disease), and treatment for infection. We can only speculate that Two patients with missing data were excluded from the analysis. Oncologists who enrolled patients with ALL in the B1931022 study (the INO-VATE study) have published on hepatic adverse events as recorded by study-site investigators. (18) Although the general conclusions of their analysis ("Treatment with InO is associated with increased hepatotoxicity, especially after follow-up HSCT, compared with standard care") is concordant with our analysis, our panel determined that the majority of adverse liver events were caused by DILI or IHC and not by hepatic sinusoidal injury (SOS). In subjects with a DILI classification, the offending drug (InO vs. standard chemotherapy vs. concomitant medication such as an antimicrobial drug) could not be identified with any certainty. We speculate that disposition of a calicheamicin metabolite by hepatocytes and subsequent biliary excretion is a possible mechanism for DILI in InO recipients, but our data do not address this hypothesis. Almost all cases of IHC were related to infection, in turn related to the effect of inflammatory cytokines (interleukin [IL]-6 and tumor necrosis factor alpha [TNFα]) on ABCC2 hepatocyte transporters of bilirubin diglucuronide. (19) (20) (21) The data show that whereas the frequency of SOS in these studies was low, this diagnosis was made only in patients who had received InO (frequency 1.5%), and the only severe SOS cases were in ALL study patients who had received InO. Several diagnoses of SOS by study-site investigators were unable to be confirmed by our panel of hepatologists. We had the advantage of being blinded to study assignment, but the disadvantage of not being at the bedside to examine patients or liver histology in the few patients who had tissue available. Our exploratory analysis of risk factors for SOS in study patients with ALL who subsequently underwent HCT found that previous InO exposure was one of several risk factors, but not the dominant factor in an exploratory multivariable analysis. InO exposure had not been examined as a potential risk factor for posttransplant SOS in the study-site analysis. (18) These data from patients with hematological malignancy receiving InO stand in contrast to a greater reported frequency of SOS and severe SOS in patients exposed to GO, an anti-CD33 ADC with the same toxic moiety (calicheamicin) as InO. Frequency of SOS following GO monotherapy varies with the cumulative dose, estimated at 3% when the GO dose was ≤6 mg/m 2 and 15% at a GO dose of 9 mg/m 2 . (22) In the clinical setting, where GO is combined with other chemotherapy drugs or in proximity to myeloablative conditioning therapy, frequency of SOS can be higher. (6, 22) In study B1931022, median overall dose of InO in patients with ALL was 4.2 mg/ m 2 and frequency of severe SOS was 2 of 164 (1.2%). A comparison of the frequency of sinusoidal liver toxicity in patients who receive InO versus GO is complicated by both different dosing schedules and the greater amount of calicheamicin in InO compared to GO. We speculate that greater sinusoidal liver toxicity from GO monotherapy, compared to that following InO exposure, is related to expression of CD33 + cells resident in normal liver, compared to absence of CD22 + cells in normal liver. Calicheamicin delivery to SECs and KCs that express CD33 is the likely mechanism behind the apparently greater sinusoidal toxicity of GO. (23, 24) Does exposure to InO increase the risk of developing SOS after a subsequent myeloablative conditioning regimen and allogeneic HCT? Data from Table 3 suggest that InO exposure in patients with ALL may increase the risk of SOS after a myeloablative conditioning regimen (21 of 79 patients who had been randomized to the InO arm developed SOS after HCT, compared to 3 of 34 from the chemotherapy arm; P = 0.0442). Moderate and severe SOS cases were also more frequent in patients from the InO arm. However, exposure to InO was not the only risk factor for development of SOS after HCT by univariate analysis and failed to enter the final multivariate model after stepwise selection, which identified a history of liver disease before randomization and thrombocytopenia before conditioning therapy as the dominant risk factors for post-HCT SOS. Although InO exposure itself was not significant in the multivariable model, it is possible that InO played a role in causing thrombocytopenia in the time period before HCT, given that delayed platelet recovery is a recognized effect of InO therapy.
The mechanisms by which InO might increase the risk of posttransplant SOS have been clarified by development of a primate model of ADC-related sinusoidal liver injury. (25) In this study, a nonbinding antibody-calicheamicin conjugate was administered to cynomolgus monkeys at doses equivalent to human exposures to GO and InO. At day 3 after exposure, there was loss of LSECs and midzonal hepatocyte degeneration; at day 63, variable LSEC recovery and sinusoidal capilliarization and dilation were observed. Although this study points to uptake of the antibody-calicheamicin conjugate as one mechanism of LSEC injury, it begs the question as to whether the results would be different if InO or GO were infused.
If InO is to be used as a bridge to allogeneic transplant in patients with ALL, future protocols should be directed at lessening the impact of myeloablative conditioning therapy on cells in hepatic sinusoids. There are two general approaches: cytoprotection of LSECs and modifications to conditioning regimens that are known to damage LSECs. Although small animal studies of toxin injury have identified potential LSEC cytoprotectants, (26) (27) (28) clinical studies have not been done, and there is concern that LSEC cytoprotection methods might cytoprotect malignant cells and lead to worse outcomes. Conditioning regimen modifications to be considered include the choice of components of these regimens-avoiding known LSEC toxins (e.g., cyclophosphamide, etoposide, and higher-dose total body irradiation); therapeutic drug monitoring to avoid exposures to high levels of toxic metabolites; optimizing the order of multidrug regimens; and limiting doses of total body irradiation. (29) (30) (31) (32) Only one therapy (defibrotide) has been U.S. Food and Drug Administration and European Medicines Agency approved for the indication SOS. However, the majority of defibrotide-treated patients on which approvals were based did not receive antibody-drug conjugates such as GO and InO. Description of liver histology at various stages of SOS following GO and InO is limited. One GO report noted intense deposition of collagen within sinusoids, without much zone 3 hemorrhage, suggesting that stellate cell activation and matrix production was a dominant feature of GO-caused sinusoidal injury. (33) Because the effectiveness of defibrotide in patients with ADC-related sinusoidal injury is unknown, and because of the cost (exceeding $100,000 USD currently), having a certain diagnosis of SOS before starting therapy would seem wise. There are mimics of SOS that are difficult to differentiate from SOS, particularly sepsis syndrome with hypotension and subsequent liver and renal dysfunction; cardiac failure with passive congestion in the liver, hypoxic hepatitis, and renal insufficiency; cholestatic liver disease related to the cytokines IL-6 and TNFα; pre-existing hepatic fibrosis and cirrhosis with decompensation related to post-transplant liver insults; and combinations of these disorders. (29) The most accurate diagnostic tools are Doppler ultrasound (detection of ascites, measurement of resistive indices to hepatic artery flow, and direction of portal venous flow) and a transvenous approach by the hepatic vein for measurement of the wedged hepatic venous pressure gradient using the Groszmann method and liver biopsy histology. (7, 34) Transvenous liver biopsy in experienced hands can be done safely in patients whose platelet count is >30,000/mm 3 using either a needle biopsy instrument by a jugular vein or a Mansfield forceps by a femoral vein. (35) Are there treatment recommendations for patients who develop SOS after InO exposure that can be derived from the data in this article? In the cohorts of patients with ALL and NHL who received InO, 5 developed SOS during the study period, of whom 3 recovered without specific treatment and 2 died with severe SOS (Table 2 ). In the cohort of ALL patients who came to subsequent HCT, 21 developed SOS, of whom 12 recovered and 9 died with severe SOS. Once a definitive diagnosis of SOS has been made, estimates of the risk that SOS will be fatal can be based on clinical, laboratory, imaging, and histologic criteria. (29) Defibrotide infusions are approved for the indication severe SOS, but data on effectiveness in treating SOS following ADC-caused SOS are limited. There is anecdotal experience with using preemptive hemofiltration to prevent massive extravascular fluid accumulation, particularly in the lungs. (36) The development of a primate model of LSEC injury following InO exposure will provide an opportunity to study prevention and treatment of LSEC damage. (25) 
